Background Current treatments with tyrosine kinase inhibitors and immune checkpoint inhibitors have limited efficacy for hepatocellular carcinoma (HCC) due to drug resistance. Emerging therapies such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback